Paying $3B: GSK tops US criminal, civil settlements for off-label, other schemes

Beating the competition is the name of the game in business. But GlaxoSmithKline's $3 billion settlement with the US government to resolve criminal and civil charges – topping rival New York-based Pfizer's $2.3 billion deal – is not likely what the London drug giant had in mind for outdoing its competitors.